AVITA Medical®, Inc | Cary Vance, Interim CEO J.P. Morgan Healthcare Conference (ASX: AVH, NASDAQ: RCEL) Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking stat ...

Financial Performance - Q3 2025 revenue was $17.1 million, a 13% decrease compared to $19.5 million in Q3 2024[13] - Operating expenses decreased by 24%, from $30.2 million in Q3 2024 to $23.0 million in Q3 2025[13] - Net loss improved by 18.5%, decreasing from $16.2 million in Q3 2024 to $13.2 million in Q3 2025[13] - Net cash use improved to $6.2 million in Q3 compared to $10.1 million in Q2[14] - The company raised $13.8 million through a private placement in August[16] Gross Margin - Gross margin was 81.3% in Q3 2025, a decrease of 240 bps compared to 83.7% in Q3 2024, while RECELL-only gross margin was 83.6% for the quarter[13] Market and Strategy - The company is focusing on approximately 200 key burn and trauma centers[11, 12] - The U S total addressable market (TAM) is estimated to be over $3.5 billion[11] - The company is active in approximately 90% of target sites, representing a $1.3 billion U S total addressable market, and currently serves approximately 5% of this TAM[12] Reimbursement - All seven Medicare Administrative Contractors (MACs) have published or confirmed payment rates for RECELL[7]